Atrophic Remodeling of the Heart In Vivo Simultaneously Activates Pathways of Protein Synthesis and Degradation

Circulation

Volumn 108, Issue 20, 2003, Pages 2536-2541

  Razeghi, Peter ^a   Sharma, Saumya ^a   Ying, Jun ^a   Li, Yi Ping ^b   Stepkowski, Stanislaw ^a   Reid, Michael B ^b   Taegtmeyer, Heinrich ^a,c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Genes; Mechanics; Proteins; Remodeling

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; POLYUBIQUITIN; PROTEIN; PROTEIN KINASE B; PROTEIN UBCH2; RAPAMYCIN; S6 KINASE; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN CONJUGATING ENZYME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HEART DISEASE; HEART MUSCLE ATROPHY; HETEROTOPIC TRANSPLANTATION; HYPOTHESIS; INHIBITION KINETICS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RAT; UPREGULATION;

NON-PROGRAMMATIC;

ANIMALS; ATROPHY; CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; MALE; ORGAN SIZE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEINS; RATS; RATS, WISTAR; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSPLANTATION, HETEROTOPIC; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN-CONJUGATING ENZYMES; VENTRICULAR REMODELING;

EID: 0345688036     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000096481.45105.13     Document Type: Article

References (26)

1. Lecker S, Soloman V, Mitch W. et al. Muscle protein breakdown and the critical role of the ubiquitin-proteosome pathway in normal and disease states. J Nutr. 1999;129:227S-237S.
2. Medina R, Wing SS, Haas A, et al. Activation of the ubiquitin-ATP-dependent proteolytic system in skeletal muscle during fasting and denervation atrophy. Biomed Biochim Acta. 1991;50:347-356.
3. +2-activated, and ubiquitin-proteasome proteolytic pathways. J Clin Invest. 1996;97:1610-1617.
4. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001;294: 1704-1708.
5. Medina R, Wing SS, Goldberg AL. Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle during starvation and denervation atrophy. Biochem J. 1995;307:631-637.
6. Schmelzle T, Hall M. TOR, a central controller of cell growth. Cell. 2000;103:253-262.
7. Bodine S, Stitt T, Gonzalez M, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol. 2001;3:1014-1019.
8. Depre C, Shipley GL, Chen W, et al. Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat Med. 1998;14: 1269-1275.
9. Li Y, Lecker S, Chen Y. et al. TNF-alpha increases ubiquitin conjugating activity in skeletal muscle by upregulating UbcH2/E220K. FASEB J. 2003:17:1048-1057.
10. Stepkowski S, Chen H, Daloze P, et al. Rapamycim, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat. Transplantation. 1991:51:22-26.
11. Gomes M, Lecker S, Jagoe R, et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A. 2001;98:14440-14445.
12. Moldawer L, Sattler F. Human immunodeficiency virus associated wasting and mechanisms associated with inflammation. Semin Oncol. 1998;25:73-81.
13. Vary T. Regulation of skeletal muscle protein turnover during sepsis. Curr Opin Clin Nutr Metab Care. 1998;1:217-224.
14. Anker S, Rauchhaus M. Insights into the pathogenesis of chronic heart failure: immune activation and cachexia. Curr Opin Cardiol. 1999;14: 211-216.
15. Tisdale M. Wasting in cancer. J Nutr. 1999;129:243S-246S.
16. Baumgarten G, Knuefermann P, Kalra D, et al. Load-dependent and -independent regulation of proinflammatory cytokine and cytokine receptor gene expression in the adult mammalian heart. Circulation. 2002;105:2192-2197.
17. Shioi T, McMullen J, Tarnavski O, et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation. 2003;107: 1664-1670.
18. Pallafacchina G, Calabria E, Serrano E, et al. A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification. Proc Natl Acad Sci U S A. 2002; 99:9213-9218.
19. Beugnet A, Tee A, Taylor P, et al. Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability. Biochem J. 2003;372:555-566.
20. Xia Y, Wen HY, Young ME, et al. mTOR and PKA signaling mediate the cardiac transcriptional response to glutamine. J Biol Chem. 2003;278: 13143-13150.
21. Kuykendall R, Rowlands B, Taegtmeyer H, et al. Biochemical consequences of protein depletion in the rabbit heart. J Surg Res. 1987;43:62-67.
22. Kadowaki M, Kanazawa T. Amino acids as regulators of proteolysis. J Nutr. 2003;133:2052S-2056S.
23. Klein I, Samarel AM, Welikson R, et al. Heterotopic cardiac transplantation decreases the capacity of rat myocardial protein synthesis. Circ Res. 1991;68:1100-1107.
24. Morkin E, Kimata S, Skillman JJ. Myosin synthesis and degradation during development of cardiac hypertrophy in the rabbit. Circ Res. 1972; 30:690-702.
25. Schoenheimer R. The Dynamic State of Body Constituents. Cambridge, Mass: Harvard University Press; 1942.
26. Patel J, McLeod L, Vries R. et al. Cellular stresses profoundly inhibit protein synthesis and modulate the states of phosphorylation of multiple translation factors. Eur J Biochem. 2002;269:3076-3085.